Garnett v. Wang

CourtDistrict Court, S.D. New York
DecidedAugust 31, 2021
Docket1:21-cv-05125
StatusUnknown

This text of Garnett v. Wang (Garnett v. Wang) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Garnett v. Wang, (S.D.N.Y. 2021).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK

ALEX GARNETT, Individually and on Behalf of All Others Similarly Situated, 21 Civ. 5125 (PAE) Plaintiff, -v- ORDER RLX TECHNOLOGY INC., YING (KATE) WANG, LONG (DAVID) JIANG, YILONG WEN, YUEDUO (RACHEL) ZHANG, COLLEEN A. DEVRIES, COGENCY GLOBAL INC., CITIGROUP GLOBAL MARKETS INC., and CHINA RENAISSANCE SECURITIES (HONG KONG) LIMITED, Defendants.

PAUL A. ENGELMAYER, District Judge: This decision appoints lead plaintiffs and counsel in a putative securities class action. On June 9, 2021, plaintiff Alex Garnett filed this action under the federal securities laws on behalf of purchasers of RLX Technology Inc. (“RLX”) securities in connection to the company’s initial public stock offering (“IPO”). Garnett claimed, infer alia, that RLX and its co-defendants! had made untrue statements of material fact and/or omitted material facts necessary to make their statements not misleading. These statements and omissions tended to conceal the facts—as alleged, known to RLX—of forthcoming regulations in China that would constrain RLX’s plan to sell vaping products and thereby tend to harm the company’s financial prospects. Garnett

Defendants are RLX; Ying (Kate) Wang, RLX’s chief executive officer and board chair; Long (David) Jiang and Yilong Wen, who were each RLX founders and directors; Yueduo (Rachel) Zhang, RLX’s head of finance; Cogency Global Inc., RLX’s authorized U.S. representative for purposes of the IPO; Colleen A. DeVries, Cogency’s senior vice president; and Citigroup Global Markets Inc. (“Citigroup”) and China Renaissance Securities (Hong Kong) Limited (“China Renaissance”), underwriters of RLX’s IPO.

alleged that, as a result of RLX’s actionable statements and omissions, he and the putative class bought RLX securities at a premium, unaware of the looming regulatory threat to RLX’s prospects. Garnett further alleges that, when the adverse regulation later became public, RLX’s share value dropped substantially, damaging him and members of the putative class, After Garnett filed suit, eight movants—ultimately not including Garnett—sought appointment as lead plaintiff. Consensus among these movants as the proper lead plaintiff(s), however, has since been reached. Pending now is a joint motion from Chien-Lung Tseng, Billy Sung, and Jerry Yue (collectively, “Prospective Lead Plaintiffs”) seeking appointment as co-lead plaintiffs and appointment of their respective attorneys as co-lead counsel. Of the eight movants who initially sought appointment as lead plaintiffs,? only Tseng, Sung, and Yue still seek such appointment. They represent that together they had the largest financial interest of the movants and contend that they are adequate and typical to represent the putative class, as Federal Rule of Civil Procedure 23 requires. Dkt. 51 (“Joint Stipulation”) at 3. The other movants have since filed notices of withdrawal or of non-opposition to Prospective Lead Plaintiffs’ motion? For the reasons that follow, the Court grants the unopposed motion, and appoints (1} Tseng, Sung, and Yue as lead plaintiffs; and (2) Wolf Haldenstein Adler Freeman & Herz LLP and Scott+Scott Attorneys at Law LLP as co-lead counsel.

The cight consist of seven individuals (two who moved jointly) and one company. The seven individuals are: (1) Chien-Lung Tseng, Dkt. 22; (2) Jun Yan, Dkt. 25; (3) Claudio Sorbara, Dkt. 28; (4) Zhang Haotian, Dkt. 29; (5) Billy Sung and (6) Jerry Yue (moving jointly), Dkt. 35; and (7) Ling Jiang, Dkt. 39. The company is Trip Consultants Limited, Dkt. 34. 3 See Notice of Non-Opposition of Claudio Sorbara, Dkt. 46; Notice of Non-Opposition of Zhang Haotian, Dkt. 47; Notice of Non-Opposition of Trip Consultants Limited, Dkt. 48; Notice of Non-Opposition of Ling Jiang, Dkt. 49; Notice of Non-Opposition by Jun Yan, Dkt. 50.

I. Background A. The FAC’s Allegations4 RLX manufactures and sells vaping products in China. Dkt. 21 (“First Amended Complaint” or “FAC”), 4 14. In January 2021, RLX undertook an IPO in New York. /d. {f 1, 3. Its American Depository Shares (“ADS”) are listed on the New York Stock Exchange under the ticker symbol “RLX.” Id. 3. On January 19, 2021, RLX filed its final registration statement, and on January 22, 2021, a final prospectus (together with the registration statement, the “Offering Documents”) in connection with the impending IPO. Jd. 25. RLX issued and sold approximately 116,500,000 ADS through the IPO, yielding gross proceeds of approximately $1.4 billion. Jd. Challenged here are two related sets of false and/or misleading statements by RLX—first, regarding its product’s prospects for being regulated under China’s tobacco licensing regime, and second, regarding RLX’s financial prospects, given such future regulation. First, RLX represented that its products would not fall under China’s tobacco monopoly system.’ It represented that “there are currently no laws and regulations which specifically govern the distribution of e-cigarettes in the PRC.” Jd. | 27 (emphasis omitted). RLX also stated that its products “are not currently defined as ‘tobacco products’ in the Tobacco Monopoly Law and its Implementation Regulation.” Jd. (emphasis omitted). RLX acknowledged that laws

* The following facts are drawn from Garnett’s First Amended Complaint (“FAC”), Dkt. 21, and the parties’ submissions on the lead plaintiff motions. The Court accepts these facts as true solely for the purpose of resolving these motions. > On June 29, 1991, the Standing Committee of the National People’s Congress of China adopted the Tobacco Monopoly Law of the PRC. FAC 4 27. It created a state-run tobacco licensing system for so-called “tobacco monopoly commodities,” including, inter alia, cigarettes, cigars, cut tobacco, and cigarette paper. Id.

and regulations on the vaping industry might affect its financial prospects, but it stated that “there are currently no clear and specific national laws, regulations, rules or standards for the sale of e-cigarettes, including e-vapor products,” except for regulations prohibiting sales to the underage and online advertisement and sales. fd, | 28 (emphasis omitted). These statements, the complaint alleges, were false and/or misleading because RLX failed to disclose that “regulators in China were already working on a national standard for e-cigarettes” that would regulate them under the same rules or in a similar way to ordinary cigarettes. Id. § 30 (emphasis omitted). Second, RLX stated that it had been, and expected to continue, profiting from China’s rapidly growing vaping market. Jd. § 29. Plaintiffs state that RLX contrasted this claim “with select financial results as a means of conveying to prospective investors that its then-existing financial condition and prospects were equally bright.” /d. (emphasis omitted). This too was misleading, plaintiffs claim, because RLX did not disclose the effect that the coming regulation of the vaping industry would have on its financial prospects. On March 22, 2021, China’s Ministry of Industry and Information Technology posted draft regulations that confirmed that e-cigarettes would be regulated like previous iterations of tobacco products. Id. 935. That day, RLX’s ADS closed at $10.15 per ADS, down nearly 48% from its previous close of $19.46 per ADS on March 19, 2021, the previous trading day. Jd. { 36. On April 23, 2021, RLX filed its Annual Report (the “2020 Annual Report”). Jd. § 37. According to plaintiffs, the 2020 Annual Report “continued and reinforced” RLX’s earlier misrepresentations in its Offering Statements with respect to RLX’s regulation and anticipated financial performance. See id. § 38.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Varghese v. China Shenghuo Pharmaceutical Holdings, Inc.
589 F. Supp. 2d 388 (S.D. New York, 2008)
Dietrich v. Bauer
192 F.R.D. 119 (S.D. New York, 2000)
Constance Sczesny Trust v. KPMG LLP
223 F.R.D. 319 (S.D. New York, 2004)
Glauser v. EVCI Career Colleges Holding Corp.
236 F.R.D. 184 (S.D. New York, 2006)
Kaplan v. Gelfond
240 F.R.D. 88 (S.D. New York, 2007)
Strougo v. Brantley Capital Corp.
243 F.R.D. 100 (S.D. New York, 2007)
Sgalambo v. McKenzie
268 F.R.D. 170 (S.D. New York, 2010)
Janbay v. Canadian Solar, Inc.
272 F.R.D. 112 (S.D. New York, 2010)
Foley v. Transocean Ltd.
272 F.R.D. 126 (S.D. New York, 2011)
In re Facebook, Inc.
288 F.R.D. 26 (S.D. New York, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
Garnett v. Wang, Counsel Stack Legal Research, https://law.counselstack.com/opinion/garnett-v-wang-nysd-2021.